ストックスクリーナーアプリを入手
13.77
4.79%
0.63
Maplight Therapeutics Inc (MPLT) 最新ニュース
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study - Business Wire
Blue Owl Capital Holdings LP Takes $26.16 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
MPLT: MapLight Therapeutics, Inc.Financial Overview - Zacks Investment Research
MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% - Stock Titan
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7%Should You Sell? - MarketBeat
MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs - Stock Titan
MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs - Stock Titan
MapLight (MPLT) Reported Results Review: The EPS Result Is Below Expectation in the Reported Period; Trading-Day Reaction: Shares Rise 5.11% in Latest TradingGuidance Downgrade Alert - Vinanet
Catalyst4 builds 49.9% MapLight (MPLT) stake in private share deal - Stock Titan
MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Therapeutics announces $150M private placement - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
LifeSci Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20 - moomoo.com
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta - Endpoints News
MapLight Therapeutics Announces $150 Million Private Placement Financing - marketscreener.com
MapLight bags USD 150m after muscarinic schizophrenia Phase II win - AllSci
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Cut to $28.77, Implies 148% Upside - TradingView
Dividend HistoryMapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Reports Positive Phase 2 Schizophrenia Data, Plans Phase 3 Trial - Minichart
MapLight Q2 Results: Net loss widens to $60.2M, cash runway extends to 2028 - scanx.trade
MapLight Therapeutics Secures $150 Million Through Private Stock Placement - Kalkine Media
MapLight Therapeutics Announces Q2 2026 Financial Results with Rising Losses and R&D Expenses - Kalkine Media
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MapLight Therapeutics (Nasdaq: MPLT) boosts cash with $150M private deal - Stock Titan
MapLight Therapeutics 2Q 2026: Net loss $60.2M, EPS $(1.32) — 10-Q Summary - TradingView
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Maplight Therapeutics (NASDAQ:MPLT) Trading Up 6.4%Here's Why - MarketBeat
Latham Advises on MapLight Therapeutics’ US$150 Million Private Placement Financing - Latham & Watkins LLP
MapLight Therapeutics secures $150 million financing - The Pharma Letter
MapLight Therapeutics stock jumps on $150M private placement By Investing.com - Investing.com Nigeria
Why is MapLight Therapeutics stock rallying today? - Investing.com
MapLight Therapeutics raises $150 million in private placement - Investing.com
Why is MapLight Therapeutics stock rallying today? By Investing.com - Investing.com South Africa
Zealand’s royalty deal; Khartis raises money for TED drug - Endpoints News
MapLight Therapeutics stock jumps on $150M private placement - Investing.com
MapLight Therapeutics Launching $150 Million Private Placement Financing - marketscreener.com
MapLight Therapeutics raises $150 million in private placement By Investing.com - Investing.com Australia
Maplight Therapeutics (MPLT) Earnings Date and Reports 2026 - MarketBeat
UBS Downgrades MapLight Therapeutics(MPLT.US) to Hold Rating, Cuts Target Price to $13 - moomoo.com
MPLT Downgraded by UBS -- Price Target Lowered to $13.00 - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Therapeutics, Inc. (MPLT) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Ther - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MapLight Therapeutics, Inc. (MPLT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 6.4%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Therapeutics, Inc. (MPLT) And Encourages Investors to Connect - ACCESS Newswire
MapLight Therapeutics, Inc. (MPLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
MapLight Therapeutics (MPLT) Gains 2.79% as Shares Push Toward Key ResistanceBPI Bull Correction - vinanet.vn
Bronstein, Gewirtz & Grossman, LLC Encourages MapLight Therapeutics, Inc. (MPLT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Maplight Therapeutics (NASDAQ:MPLT) Insider Sells 22,082 Shares of Stock - MarketBeat
Form 13D/A MapLight Therapeutics For: 3 August By Investing.com - Investing.com Canada
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law - TradingView
MapLight Therapeutics, Inc. (MPLT) stock price, news, quote and history - uk.finance.yahoo.com
MapLight Therapeutics (MPLT) Drops 7.2%: Biotech Stock Nears Critical Support at $12.37Take Profit Levels - vinanet.vn
Maplight Therapeutics (NASDAQ:MPLT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):